Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Small Molecule Targeted Therapy Market Forecast: What Value Will The Market Reach By 2030?
The market size for small molecule targeted therapy has experienced significant growth in recent years. It will grow from $77.29 billion in 2025 to $84.66 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The expansion witnessed during the historic period can be attributed to progress in molecular biology research, the increasing occurrence of chronic diseases, the enlargement of pharmaceutical R&D pipelines, the regulatory approval of targeted therapies, and advancements in drug screening technologies.
The small molecule targeted therapy market is anticipated to exhibit substantial growth in the forthcoming years. It is projected to expand to $120.64 billion in 2030, achieving a compound annual growth rate (CAGR) of 9.3%. This expansion during the forecast period is fueled by several factors, including the increasing demand for personalized medicine approaches, the rising integration of genomics into drug development, the extension of targeted therapies beyond oncology, a heightened focus on designing drugs optimized for safety, and increased investment in precision therapeutics. Significant trends expected during this time involve the increasing expansion of target-specific drug development, the rising use of pathway-modulating therapies, growing adoption of oral small molecule treatments, an enhanced focus on disease-specific molecular targets, and the broader application of combination small molecule regimens.
Get A Free Sample Report With In-Depth Market Insights:
Small Molecule Targeted Therapy Market Demand Drivers: What’s Powering Industry Growth?
The escalating prioritization of personalized medicine is anticipated to stimulate the expansion of the small molecule targeted therapy market moving forward. Personalized medicine is defined as a healthcare methodology that customizes prevention, diagnosis, and treatment according to an individual’s genetic, environmental, and lifestyle factors. The rise of personalized medicine is propelled by breakthroughs in genomics, which enable a more thorough understanding of individual genetic variations and facilitate more precise, targeted treatments that improve patient outcomes and reduce trial-and-error in therapies. Small molecule targeted therapy contributes to personalized medicine by specifically aiming at a patient’s unique molecular or genetic disease profile, enhancing treatment efficacy and lessening side effects. For instance, in February 2024, as per the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA granted approval to 16 new personalized treatments for rare disease patients, an increase from six in 2022. The newly approved personalized treatments for 2023 additionally comprised seven cancer drugs and three for other diseases and conditions. Therefore, the growing emphasis on personalized medicine is driving the growth of the small molecule targeted therapy market.
Small Molecule Targeted Therapy Market Segment Landscape: Which Areas Lead Development?
The small molecule targeted therapy market covered in this report is segmented –
1) By Type Of Therapy: Chemotherapy, Targeted Therapy, Immunotherapy
2) By Drug Class: Monoclonal Antibodies, Small Molecule Inhibitors, Combination Therapies
3) By Mechanism Of Action: Kinase Inhibitors, Proteasome Inhibitors, Aromatic Hydrocarbon Receptor (Ahr) Modulators, Cell Cycle Inhibitors
4) By Disease Indication: Cancer, Autoimmune Diseases, Infectious Diseases
5) By Route Of Administration: Oral, Intravenous, Subcutaneous
Subsegments:
1) By Chemotherapy: Alkylating Agents, Antimetabolites, Anti-microtubule Agents
2) By Targeted Therapy: Kinase Inhibitors, Proteasome Inhibitors, Aromatic Hydrocarbon Receptor (AhR) Modulators
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies
Small Molecule Targeted Therapy Market Innovation Trends: What Developments Are Reshaping The Industry?
Major companies operating within the small molecule targeted therapy sector are prioritizing the development of innovative solutions, such as oral small molecules, to enhance targeted delivery, improve patient compliance, and address specific molecular pathways in oncology and other chronic diseases. An oral small molecule is defined as a low-molecular-weight drug that can be administered by mouth, designed to easily enter cells and specifically target disease-related proteins or pathways. For example, in June 2025, Kura Oncology Inc., a US-based biotech company, received FDA approval for a New Drug Application (NDA) for ziftomenib to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) with nucleophosmin 1 (NPM1) mutations. This oral targeted therapy is specifically formulated for adult patients with relapsed or refractory AML carrying NPM1 mutations, thereby addressing a critical unmet medical need. It features a favorable safety profile and has shown encouraging efficacy, including significant complete remission rates in clinical trials. By selectively inhibiting the menin-KMT2A interaction, ziftomenib disrupts leukemic cell growth and supports new therapeutic options for this hard-to-treat AML subtype.
Small Molecule Targeted Therapy Market Industry Leaders And Competitive Landscape
Major companies operating in the small molecule targeted therapy market are F. Hoffmann-La Roche AG (Roche), Merck KGaA, Pfizer Inc., Bayer AG, Sanofi S.A., Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, Blueprint Medicines Corporation, Kura Oncology Inc., G1 Therapeutics Inc., Ascentage Pharma Group International Inc., Rgenta Therapeutics Inc., Verastem Inc.
View The Full Small Molecule Targeted Therapy Market Report:
Small Molecule Targeted Therapy Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the small molecule targeted therapy market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the small molecule targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model